Friday, August 14, 2026
Knowledge FilesExploreSearch
Via News
Facts you can rely on·101 entities·4,806 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

View original at finance.yahoo.com
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials

    80% confidence

  • There are people interested in addressing their weight who have been waiting for a medicine that was right for them, and for many that wait is over with Wegovy pill offering powerful efficacy in a once-daily pill

    80% confidence

  • More than 100 million Americans are living with obesity

    80% confidence

  • Obesity is not just a disease of lack of willpower but has underlying biology that may impede people from losing weight and keeping it off

    80% confidence

  • Wegovy pill represents a significant innovation as the first and only GLP-1 pill for weight loss

    80% confidence

  • Millions have been prescribed Wegovy (semaglutide) injection 2.4 mg for weight management since 2021

    80% confidence

Data points we hold from this source

Novo Nordisk A/S · us employee count10000 employees